griseofulvin and Mouth-Diseases

Thirty-one patients who had lichen planus treated with griseofulvin were randomly selected for review from a group of patients with lichen planus seen at the Mayo Clinic between January 1976 and June 1980; two patients were excluded because of lack of adequate follow-up. Of the 11 patients with only oral lesions, 6 showed a marked improvement or complete remission. Of the 18 patients with lichen planus involving one or more sites with or without oral lesions, 15 had cutaneous lesions. Three of the 15 had improvement of their cutaneous lesions; however, 1 of the 3 continued to develop new lesions, although old ones were improving. In patients with recalcitrant, symptomatic oral lichen planus, a trial of griseofulvin would seem justified. Success in patients with cutaneous lichen planus is less likely; however, griseofulvin may afford relief in selected patients. This study indicates that further prospective studies are needed to clarify the efficacy of griseofulvin in lichen planus.

Topics: Adult; Aged; Clinical Trials as Topic; Female; Griseofulvin; Humans; Lichen Planus; Male; Middle Aged; Mouth Diseases; Retrospective Studies; Skin

An open trial was conducted of systemic griseofulvin in the treatment of oral lichen planus. Eleven patients completed the trial. Symptomatic benefit was noted in 21% of the twenty-three patients starting the trial, but there was no clinical improvement, and about one half of the group starting the trial suffered adverse drug reactions.

Topics: Administration, Oral; Griseofulvin; Headache; Humans; Lichen Planus; Mouth Diseases; Nausea; Tablets; Treatment Failure

Lichen planus is one of the most common dermatologic diseases involving the skin and oral mucous membranes. It may occur anywhere in the oral cavity. Erosive lichen planus has been reported to undergo malignant transformation, making definitive diagnosis, treatment, and followup essential. The purpose of this study was to establish the effectiveness of griseofulvin therapy on erosive lichen planus and to provide an alternative to steroid therapy. The results of this study revealed that griseofulvin had little or no effect on pain, pigmentation, or disappearance of erosive lichen planus and did not protect the patient from further recurrences.

Topics: Adult; Aged; Female; Griseofulvin; Humans; Lichen Planus; Male; Middle Aged; Mouth Diseases; Pain; Recurrence

Topics: Griseofulvin; Humans; Lichen Planus; Male; Middle Aged; Mouth Diseases

Lichen planus of the oral cavity produces significant functional and symptomatic problems for elderly patients. Oral lesions often occur in the absence of concomitant skin lesions. Unlike cutaneous lesions, oral lesions of lichen planus may become a chronic, recurring problem that is difficult to control. The diagnostic features of lichen planus of the oral cavity are reviewed and treatment strategies presented. Periodic follow-up is recommended to monitor the disease process and to observe for the development of early squamous cell carcinoma.

Topics: Administration, Topical; Aged; Anti-Inflammatory Agents; Female; Glucocorticoids; Griseofulvin; Humans; Lichen Planus; Male; Mouth Diseases; Mouth Mucosa; Vitamin A

Seven patients with lichen planus of the oral mucosa (four with erosive and three with reticular types of the disease) were studied; they were treated with 500 mg of griseofulvin twice daily for 2 1/2 months. In no case was improvement observed; on the contrary, in four patients (two with erosive and two with reticular forms) the condition worsened.

Topics: Adult; Aged; Female; Follow-Up Studies; Griseofulvin; Humans; Lichen Planus; Male; Middle Aged; Mouth Diseases

We report three cases of erosive oral lichen planus treated with griseofulvin, 500 mg. twice a day. Subjective improvement was noticed in 3 weeks by two patients and at 6 weeks by the third patient. Objective improvement, however, was delayed and became apparent at 6 to 10 weeks. Continued improvement or remission without exacerbation was noted in all patients. There were no significant hematologic, hepatic, or other side effects in any patient, and complete blood count and blood chemistries remained normal at 1-month as well as 6-month intervals during therapy. All patients did, however, report mild, transient gastrointestinal discomfort during the first 2 days of therapy, and one patient mentioned a mild headache. These remitted after approximately 2 to 4 days. We believe that these preliminary findings warrant additional trials of griseofulvin therapy in the treatment of severely symptomatic oral lichen planus. The adverse effects of this agent appear considerably less than those of systemic steroids.

Topics: Aged; Female; Griseofulvin; Humans; Lichen Planus; Middle Aged; Mouth Diseases; Time Factors

Topics: Amphotericin B; Antifungal Agents; Candida albicans; Candidiasis; Candidiasis, Oral; Diaper Rash; Drug Resistance, Microbial; Female; Griseofulvin; Humans; Male; Mouth Diseases; Nystatin; Ointments; Paronychia; Pruritus Ani; Skin Diseases; Tinea; Tinea Pedis; Tinea Versicolor